Core Insights - BD (Becton, Dickinson and Company) has announced the initiation of the first pharma-sponsored clinical trial utilizing the BD Libertas™ Wearable Injector for the subcutaneous delivery of complex biologics [1][2] - The trial follows successful outcomes from over 50 pre-clinical and clinical studies conducted by BD, with 100% of participants indicating a likelihood of using the device if prescribed [2][3] Company Commitment and Innovation - The trial signifies BD's commitment to advancing drug-device combination products, enhancing patient care by allowing self-injection at home instead of requiring hospital visits [3][4] - BD's acquisition of enhanced testing capabilities through ZebraSci positions the company as a leader in drug delivery, focusing on large-volume injection science [4] Market Potential - The biologics market is projected to exceed $670 billion by 2030, indicating significant growth opportunities for pharmaceutical companies developing complex drugs [4] - The BD Libertas™ Wearable Injector offers a customizable, patient-centric solution for the delivery of these biologics [4] Product Features - The BD Libertas™ Wearable Injector supports the delivery of high-viscosity biologics (up to 50 centipoise) and is available in 2 to 5 mL and 5 to 10 mL configurations [8] - The device features a fully mechanical design that is ready-to-use, requiring no end-user filling or assembly, which enhances user convenience [8]